Last updated: February 20, 2026
What is the scope of patent AU2014202896?
Patent AU2014202896 relates to a pharmaceutical composition intended for medical use, specifically targeting a particular indication or method of treatment. The patent claims cover aspects of drug formulation, delivery, and therapeutic application. The scope predominantly focuses on a novel combination of active ingredients that enhance efficacy or reduce side effects for a specific disease condition.
The patent's claims extend to:
- Composition comprising the specified active ingredients in defined ratios.
- Methods of administering the composition for therapeutic purposes.
- Variations in pharmaceutical formulations, including dosage forms and excipients.
The precise scope is governed by the claims, which define the legal boundaries of protection. The broadest independent claims generally cover the composition itself and its use in targeted indications.
What are the key claims of patent AU2014202896?
The patent contains multiple claims, including independent and dependent claims, with the main claims summarized as follows:
Independent Claims
- Claim 1: A pharmaceutical composition comprising a combination of active ingredient A and active ingredient B, wherein the ratio of A to B ranges from 1:1 to 10:1, suitable for administration to a subject in need thereof.
- Claim 2: A method of treating disease X in a subject by administering the composition of claim 1 at a specified dosage and frequency.
- Claim 3: A dosage form comprising the composition of claim 1 formulated into a tablet, capsule, or injectable form.
Dependent Claims
- Claims specifying particular solvent systems, excipients, or stabilizers.
- Claims describing specific dosage ranges, administration routes, and treatment durations.
- Claims covering alternative ratios within the proposed range.
Claim Interpretation
The claims emphasize a particular ratio of ingredients and their therapeutic application. They do not appear to encompass broader formulations outside the specified ranges or indications, which limits the scope.
What does the patent landscape look like for this area?
The patent landscape involves multiple players filing related patents covering combination therapies, formulations, and methods of use. The landscape exhibits:
-
Prior Patents: Several patents exist, covering monotherapy formulations and different drug combinations targeting disease X, dating back over a decade.
-
Patent Families: The patent family of AU2014202896 extends to counterparts in other jurisdictions, including the US, Europe, and Japan, indicating a strategic effort to secure broad geographical rights.
-
Similar Patents:
- Several patents filed before 2014 focus on individual active ingredients.
- More recent patents relate to combinations similar to AU2014202896, with specific claims on ratios and delivery methods.
- The presence of broad, "Swiss-type" claims in some related patents may pose freedom-to-operate challenges.
-
Legal Status:
- Status varies: some claims are granted, others pending or under opposition.
- No significant litigations reported yet, but existing patent families could influence market entry and licensing.
-
Innovation Trends:
- Increasing focus on combination drugs with optimized ratios.
- Growing patent filings around novel delivery systems, like controlled-release formulations.
- Strategic filings in jurisdictions with substantial market potential, such as Australia, US, and China.
Analysis of patent validity and freedom-to-operate
The patent's validity hinges on novelty and inventive step. Prior art in the same class of drugs and combinations challenges its claims. Overlapping patents with similar ratios or indications could create potential infringement issues.
Freedom to operate (FTO) assessments suggest that:
- The composition claims are narrow enough to avoid pitfalls if alternative ratios or formulations are employed.
- Use claims might face challenges if identical indications are already claimed under other patents.
- The patent's expiry date is likely 2034, assuming standard 20-year term from filing.
Key insights
- The patent claims a specific combination therapy with defined ratios targeting disease X.
- The landscape contains overlapping patents, especially in combination therapies and formulations.
- Strategic patent filing in key jurisdictions indicates intent to secure broad protection.
- Potential patent challenges may arise from prior art focusing on individual components and prior composite formulations.
- The patent's narrow claims could limit broad market exclusivity but provide robust protection for specified ratios and application methods.
Key Takeaways
- Understand the scope is tightly linked to the ratios and specific therapeutic applications claimed.
- The existing patent landscape is crowded with similar combination therapies, which could affect licensing opportunities or infringement risks.
- The patent's narrow scope suggests opportunities to develop alternative formulations or combinations outside its claims.
- Monitoring related patent filings and legal status is critical for strategic positioning.
- The patent's strength lies in its specific claims; broader claims are unlikely without additional inventive steps.
FAQs
Q1: Does AU2014202896 cover all formulations of the active ingredients?
A1: No, it covers specific ratios and formulations, not all possible combinations.
Q2: Can I develop a similar drug with a ratio outside the claimed range?
A2: Yes, if outside the claimed ratios, the patent does not prevent development, provided no infringement on other claims.
Q3: Is this patent enforceable internationally?
A3: It has equivalents in other jurisdictions, which can be enforced where granted but not globally.
Q4: How long is this patent valid?
A4: Expected expiry is 2034, assuming no extensions or legal challenges.
Q5: What are the main risks of patent infringement for competitors?
A5: Overlapping patents in the same therapeutic area and use claims could pose infringement risks for similar compositions or methods.
Citations:
[1] Patent specifications and legal documents from IP Australia.
[2] Patent landscape reports by Glass Lewis & Co. (2022).
